The purpose of this study is to verify the post-market safety of the IC-8 Apthera IOL after the treatment of posterior capsular opacification (PCO), an expected complication related to IC-8 Apthera IOL implantation.
Age range
22 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Rate of any additional Nd:YAG laser treatments beyond the initial Nd:YAG laser treatment
Timeframe: 24 Months post IC-8 Apthera IOL Implantation
Nd:YAG laser treatment outcome and/or complications
Timeframe: 24 Months post IC-8 Apthera IOL Implantation
IOL related assessments
Timeframe: 24 Months post IC-8 Apthera IOL implantation
Rates of Secondary Surgical Interventions (SSIs)
Timeframe: 24 Months post IC-8 Apthera IOL implantation
Rates of other serious adverse events
Timeframe: 24 Months post IC-8 Apthera IOL implantation
Rates of ocular adverse events
Timeframe: 24 Months post IC-8 Apthera IOL implantation
Rates of subjective visual disturbances per the Quality of Vision (QoV) Questionnaire
Timeframe: 24 Months post IC-8 Apthera IOL implantation
Rates of subjective visual disturbances per the Small Aperture Patient Questionnaire (SAPQ)
Timeframe: 24 Months post IC-8 Apthera IOL implantation